Published in Hepatitis Weekly, March 29th, 2004
This notice of allowance, in addition to patent numbers 6,605,593 and 6,613,739, pertains to Isotechnika's lead drug compound, ISA247. ISA247 is a novel immunosuppressive drug currently being investigated for the prevention of organ rejection in kidney transplant patients and in the treatment of psoriasis.
Joseph Koziak, executive vice president of Isotechnika, stated, "This notice of allowance represents the third patent approval for ISA247 in our primary market of the United States...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.